| 1.48 0 (0%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.59  |
1-year : | 6.54 |
| Resists | First : | 3.93 |
Second : | 5.59 |
| Pivot price | 2.45 |
|||
| Supports | First : | 1.25 |
Second : | 1.03 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 3.06 |
| MA(100) : | 5.27 |
MA(250) : | 0 | |
| MACD | MACD : | -1  |
Signal : | -0.9 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 2 |
| RSI | RSI(14): 15.2 | |||
| 52-week | High : | 99.96 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELAB ] has closed above bottom band by 25.7%. Bollinger Bands are 56.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.67 - 1.68 | 1.68 - 1.69 |
| Low: | 1.23 - 1.24 | 1.24 - 1.25 |
| Close: | 1.46 - 1.48 | 1.48 - 1.49 |
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Mon, 22 Dec 2025
PMGC Holdings Inc Announces Key Developments in Subsidiaries - TradingView — Track All Markets
Wed, 17 Dec 2025
Time to Buy or Sell ELAB? - timothysykes.com
Thu, 04 Dec 2025
PMGC Holdings Inc. Supports General Enterprise Ventures, Inc. in Successful NYSE American Uplisting - Quiver Quantitative
Thu, 04 Dec 2025
PMGC Holdings (Nasdaq: ELAB) Backs GEVI as CitroTech Fire Tech Gains NYSE American Listing - Stock Titan
Thu, 04 Dec 2025
PMGC Holdings Inc. [Nasdaq: ELAB] Congratulates General - GlobeNewswire
Tue, 14 Oct 2025
PMGC Holdings Stock Jumps 230% Premarket, Grabs Retail Eyeballs - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 9.1 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 57 (K) |
| Shares Short P.Month | 89 (K) |
| EPS | 399.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.4 |
| Profit Margin | 0 % |
| Operating Margin | -752.1 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -76.2 % |
| Qtrly Rev. Growth | -45.8 % |
| Gross Profit (p.s.) | -0.32 |
| Sales Per Share | 0.38 |
| EBITDA (p.s.) | -7.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.12 |
| Price to Sales | 3.85 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|